

GENERAL ASSEMBLY OF NORTH CAROLINA
SESSION 2021

S

4

SENATE BILL 711
Judiciary Committee Substitute Adopted 7/1/21
Finance Committee Substitute Adopted 7/21/21
Judiciary Committee Substitute Adopted 8/25/21

Short Title: NC Compassionate Care Act.

(Public)

Sponsors:

Referred to:

April 8, 2021

1 A BILL TO BE ENTITLED
2 AN ACT ENACTING THE NORTH CAROLINA COMPASSIONATE CARE ACT.

3 The General Assembly of North Carolina enacts:

4 **SECTION 1.** Chapter 90 of the General Statutes is amended by adding a new Article
5 to read:

6 "Article 5H.

7 "North Carolina Compassionate Care Act.

8 **"§ 90-113.110. Short title.**

9 This Article shall be known and may be cited as the "North Carolina Compassionate Care
10 Act."

11 **"§ 90-113.111. Legislative findings and purpose.**

12 The General Assembly makes the following findings:

13 (1) Modern medical research has found that cannabis and cannabinoid
14 compounds are effective at alleviating pain, nausea, and other symptoms
15 associated with several debilitating medical conditions.

16 (2) As of May 2021, 36 states and the District of Columbia have removed
17 state-level criminal penalties for the medical use, cultivation, and distribution
18 of cannabis, and in enacting this Article, North Carolina now takes similar
19 action to preserve and enhance the health and welfare of its citizens.

20 (3) This Article is intended to make only those changes to existing North Carolina
21 laws that are necessary to protect patients and their doctors from criminal and
22 civil penalties and is not intended to change current civil and criminal laws
23 governing the use of cannabis for nonmedical purposes.

24 (4) The General Assembly enacts this Article pursuant to its police power to enact
25 legislation for the protection of the health of its citizens, as reserved to the
26 State in the Tenth Amendment of the United States Constitution.

27 **"§ 90-113.112. Definitions.**

28 The following definitions apply in this Article:

29 (1) Adequate supply. – An amount of usable cannabis derived solely from an
30 intrastate source that is possessed by a qualified patient, or collectively
31 possessed by a qualified patient and the qualified patient's designated
32 caregiver, in an amount that does not exceed what is reasonably necessary to
33 assure the uninterrupted availability of cannabis for a period of 30 days, in any
34 form recommended by the qualified patient's physician for the purpose of



* S 7 1 1 - V - 4 *

- 1 alleviating the symptoms or effects of the qualified patient's debilitating
2 medical condition.
- 3 (2) Advisory Board. – The Compassionate Use Advisory Board established in
4 G.S. 90-113.113.
- 5 (3) Bona fide physician-patient relationship. – A treatment relationship between
6 a physician and a patient in which the physician has completed a full
7 assessment of the patient's medical history, including checking the patient's
8 prescription history in the Controlled Substances Reporting System, and
9 current medical condition, including an in-person physical examination, and
10 the physician is available or offers to provide follow-up care and treatment to
11 the patient, including patient examinations, to determine the efficacy of the
12 use of cannabis as a treatment for the patient's medical condition.
- 13 (4) Cannabis. – Marijuana as defined in G.S. 90-87(16).
- 14 (5) Cannabis-infused product. – A product infused with cannabis that is intended
15 for use or consumption other than by inhalation, smoking, or vaping. The term
16 includes a tablet, a capsule, a concentrated liquid or viscous oil, a liquid
17 suspension, a topical preparation, a transdermal preparation, a sublingual
18 preparation, a gelatinous cube, a gelatinous rectangular cuboid, a lozenge in a
19 cube or rectangular cuboid shape, a resin, or a wax.
- 20 (6) Commission. – The Medical Cannabis Production Commission established in
21 G.S. 90-113.117.
- 22 (7) Debilitating medical condition. – A diagnosis of one or more of the following
23 for which a physician provides a written certification:
- 24 a. Cancer.
- 25 b. Epilepsy.
- 26 c. Positive status for human immunodeficiency virus (HIV).
- 27 d. Acquired immune deficiency syndrome (AIDS).
- 28 e. Amyotrophic lateral sclerosis (ALS).
- 29 f. Crohn's disease.
- 30 g. Sickle cell anemia.
- 31 h. Parkinson's disease.
- 32 i. Post-traumatic stress disorder, subject to evidence that an applicant
33 experienced one or more traumatic events. Acceptable evidence shall
34 include, but is not limited to, proof of military service in an active
35 combat zone, that the person was the victim of a violent or sexual
36 crime, or that the person was a first responder. Details of the trauma
37 shall not be required.
- 38 j. Multiple sclerosis.
- 39 k. Cachexia or wasting syndrome.
- 40 l. Severe or persistent nausea in a person who is not pregnant that is
41 related to end-of-life or hospice care, or who is bedridden or
42 homebound because of a condition.
- 43 m. A terminal illness when the patient's remaining life expectancy is less
44 than six months.
- 45 n. A condition resulting in the individual receiving hospice care.
- 46 o. Any other serious medical condition or its treatment added by the
47 Compassionate Use Advisory Board, as provided for in
48 G.S. 90-113.113.
- 49 (8) Department. – The North Carolina Department of Health and Human
50 Services.

- 1 (9) Designated caregiver. – A person who possesses a valid registry identification
2 card issued by the Department authorizing the person to assist a qualifying
3 patient with the medical use of cannabis. A designated caregiver shall be at
4 least 21 years of age unless the person is the parent or legal guardian of each
5 qualifying patient the person assists.
- 6 (10) Medical cannabis center. – A facility owned and operated by a supplier that
7 possesses and dispenses cannabis and cannabis-infused products to registry
8 identification cardholders for human consumption.
- 9 (11) Medical use of cannabis or medical use. – The acquisition, administration,
10 possession, preparation, transportation, or use of cannabis and
11 cannabis-infused products, or paraphernalia used to administer cannabis
12 products, to treat or alleviate a qualifying patient's debilitating medical
13 condition or symptoms associated with the qualifying patient's debilitating
14 medical condition and includes the transfer of cannabis products from a
15 designated caregiver to a qualifying patient whom the designated caregiver is
16 authorized to assist. "Medical use" does not include the extraction of resin
17 from cannabis by solvent extraction other than water, glycerin, propylene
18 glycol, vegetable oil, or food grade ethanol (ethyl alcohol), unless the
19 extraction is done by a processing facility.
- 20 (12) Physician. – A person licensed under Article 1 of Chapter 90 of the General
21 Statutes who is in good standing to practice medicine in the State.
- 22 (13) Production facility. – A facility owned and operated by a supplier that
23 cultivates, possesses, and produces cannabis and cannabis-infused products.
- 24 (14) Qualified patient. – A person who has been diagnosed by a physician as
25 having a debilitating medical condition and has received a written
26 certification.
- 27 (15) Registry identification card. – A document issued by the North Carolina
28 Department of Health and Human Services pursuant to G.S. 90-113.115 that
29 identifies a person as a qualified patient or a designated caregiver.
- 30 (16) Registry identification cardholder. – A qualified patient or a designated
31 caregiver who holds a valid registry identification card issued by the North
32 Carolina Department of Health and Human Services pursuant to
33 G.S. 90-113.115.
- 34 (17) Regulated medical cannabis supply system or system. – A system established
35 by the North Carolina Department of Health and Human Services pursuant to
36 G.S. 90-113.119 to provide a safe method for producing and distributing
37 cannabis and cannabis-infused products to registry identification cardholders.
- 38 (18) Smoking. – The use or possession of a lighted cannabis product.
- 39 (19) Supplier. – A person licensed pursuant to G.S. 90-113.119 to supply cannabis
40 and cannabis-infused products as authorized by this Article. A supplier
41 cultivates cannabis, owns and operates one or more medical cannabis centers,
42 and owns and operates one or more production facilities as set forth in
43 G.S. 90-113.119.
- 44 (20) Usable cannabis. – The dried buds and mature female flowers of the plant of
45 the genus Cannabis, and any mixture or preparation thereof, that are
46 appropriate for medical use as provided in this Article.
- 47 (21) Vaping. – The use of a product which heats a liquid or other form of cannabis
48 in a manner so as to release an aerosol.
- 49 (22) Written certification. – A statement signed by a physician with whom the
50 patient has a bona fide physician-patient relationship indicating the following:

- a. In the physician's professional opinion, the patient has a debilitating medical condition.
- b. The patient's debilitating medical condition.
- c. In the physician's professional opinion, the potential health benefits of the medical use of cannabis would likely outweigh the health risk for the patient.
- d. The delivery method of the cannabis.
- e. The amount and dosage of the cannabis or cannabis-infused product, not to exceed an adequate supply.
- f. The period of time for which the written certification is valid, not to exceed one year.

"§ 90-113.113. Compassionate Use Advisory Board; membership; terms; meetings; quorum; expenses.

(a) Advisory Board Established. – The Compassionate Use Advisory Board is established and shall consist of 13 members as follows:

(1) The Governor shall appoint members to the Advisory Board as follows:

- a. A physician specializing in pain management.
- b. A general physician.
- c. A physician specializing in osteopathic medicine.
- d. A physician who is board-certified to practice addiction medicine in North Carolina.
- e. A research scientist with expertise in the field of cannabinoid medicine.
- f. A licensed pharmacist.
- g. A registry identification cardholder or, for an appointment made before registry identification cards are issued, one person with a debilitating medical condition who intends to use cannabis.
- h. A parent of a minor qualified patient or, for an appointment made before registry identification cards are issued, one parent of a minor with a debilitating medical condition who intends to use cannabis.
- i. A representative of a licensed supplier or, for an appointment made before suppliers are licensed, a prospective supplier.

(2) Two members appointed by the General Assembly upon recommendation of the Speaker of the House of Representatives in accordance with G.S. 120-121.

(3) Two members appointed by the General Assembly upon recommendation of the President Pro Tempore of the Senate in accordance with G.S. 120-121.

(b) Terms. – Members of the Advisory Board shall serve a four-year term, beginning effective July 1 of the year of appointment, and may be reappointed to a second four-year term.

(c) Chair. – The members of the Advisory Board shall elect a chair. The chair shall serve a two-year term and may be reelected.

(d) Vacancies. – Any appointment to fill a vacancy on the Advisory Board created by the resignation, dismissal, death, or disability of a member shall be made by the original appointing authority and shall be for the balance of the unexpired term.

(e) Meetings. – The Advisory Board shall meet at least two times per year for the purpose of reviewing petitions to add debilitating medical conditions.

(f) Power. – The Advisory Board shall have the power to approve adding a debilitating medical condition by a majority vote of the members present and voting.

(g) Quorum. – Seven members of the Advisory Board shall constitute a quorum for the transaction of business.

(h) Expenses. – The members of the Advisory Board shall receive per diem and necessary travel and subsistence expenses in accordance with the provisions of G.S. 138-5.

1 **"§ 90-113.114. Physician requirements.**

2 (a) Required Education. – Before providing a written certification to a qualified patient,
3 a physician shall complete a three-hour continuing medical education course on cannabis and an
4 annual one-hour supplemental medical education course thereafter, as approved by the North
5 Carolina Medical Board. Records documenting compliance must be maintained for six
6 consecutive years and may be inspected by the Department or by the North Carolina Medical
7 Board or its agents.

8 (b) Registration of Written Certification. – A physician shall register a written
9 certification for a qualified patient in the medical cannabis registry database in an electronic
10 manner as specified by the Department.

11 (c) Reevaluation. – A physician shall reevaluate an existing qualified patient as needed
12 to determine the efficacy of the use of cannabis as a treatment for the patient's medical condition,
13 at least one time per year, to include an in-person physical examination and checking of the
14 patient's prescription history in the Controlled Substances Reporting System.

15 (d) Duty to Update. – A physician shall update the medical cannabis registry database
16 within seven days after any change is made to the original written certification to reflect such
17 change, including deactivation of a written certification.

18 (e) Education Requirement. – A physician shall provide education to a qualified patient
19 on the risk and symptoms of cannabis use disorder and cannabis-induced psychosis upon initial
20 written certification and at least annually thereafter.

21 (f) Restrictions. – A physician who provides written certifications to qualified patients
22 may not be employed by or have any direct or indirect economic interest in a supplier or cannabis
23 testing laboratory. A physician may not evaluate patients or advertise on the site of a medical
24 cannabis center.

25 **"§ 90-113.115. Registry identification cards for qualified patients and designated**
26 **caregivers.**

27 (a) Applications, Issuance, and Expiration of Registry Identification Cards. – The
28 Department shall issue or renew a registry identification card to the following individuals:

29 (1) Any individual who applies to the Department on forms prescribed by the
30 Department demonstrating that the individual is a qualified patient with a
31 debilitating medical condition for which a physician has issued a written
32 certification.

33 (2) Any individual who is at least 21 years of age who has (i) been named as a
34 designated caregiver in a registry identification card application submitted by
35 a qualified patient and (ii) agreed to serve as that qualified patient's designated
36 caregiver. The Department may issue a registry identification card to a
37 maximum of two designated caregivers named in a qualified patient's
38 approved application.

39 The Department shall issue a registry identification card to an applicant within 14 business
40 days after approving an application or renewal. The initial or renewal registry identification card
41 expires one year after the date of issuance.

42 (b) Qualified Patients Under Age 18. – The Department may not issue or renew a registry
43 identification card to a qualified patient under 18 years of age unless each of the following criteria
44 is met:

45 (1) The qualified patient's physician has explained the potential risks and benefits
46 of the medical use of cannabis to the qualified patient and to a parent,
47 guardian, or person having legal custody of the qualified patient.

48 (2) The qualified patient's physician restricts the qualified patient's use of
49 cannabis to a noninhalation consumption method, and the qualified patient
50 and the qualified patient's designated caregivers agree to comply with this
51 restriction.

1 (3) A parent, guardian, or person having legal custody of the qualified patient
2 consents in writing to (i) allow the qualified patient's medical use of cannabis,
3 (ii) serve as one of the qualified patient's designated caregivers, and (iii)
4 control the acquisition of the cannabis, the dosage, and the frequency of the
5 medical use of cannabis by the qualified patient.

6 (c) Review of Applications. – The Department shall verify the information contained in
7 a registry identification card application or renewal application submitted pursuant to this section
8 and shall approve or deny an application or renewal application within 45 days after receipt.

9 (d) Denials and Appeals. – The Department may deny a registry identification card
10 application or renewal application only if the applicant fails to provide the information required
11 pursuant to this section or if the Department determines that the application or renewal
12 application contains false information. Denials may be appealed by filing a contested case
13 petition under Article 3 of Chapter 150B of the General Statutes. Article 4 of Chapter 150B of
14 the General Statutes governs judicial review of an administrative decision made under this
15 section.

16 (e) Registry Identification Card Information. – Each registry identification card issued
17 by the Department shall be printed with tamper-resistant technology and shall contain at least all
18 of the following information:

19 (1) The name of the cardholder.

20 (2) The address of the cardholder.

21 (3) The cardholder's date of birth.

22 (4) A designation of whether the cardholder is a designated caregiver or
23 qualifying patient.

24 (5) The date of issuance and expiration date of the registry identification card.

25 (6) A random alphanumeric identification number that is unique to the cardholder.

26 (7) If the cardholder is a designated caregiver, the random alphanumeric
27 identification number of the qualifying patients that the designated caregiver
28 is authorized to assist.

29 (8) A photograph of the cardholder.

30 (9) The delivery method of the cannabis.

31 (f) Notification of Changes. – Individuals issued registry identification cards are subject
32 to all of the following:

33 (1) A qualified patient who has been issued a registry identification card shall
34 notify the Department of any change in the qualified patient's name, address,
35 or designated caregiver and submit a fifty dollar (\$50.00) fee to the
36 Department within 15 days after the change occurs. A qualified patient who
37 fails to notify the Department of any of these changes within the specified
38 time frame commits an infraction and is subject to a fine not to exceed one
39 hundred dollars (\$100.00).

40 (2) A designated caregiver shall notify the Department of any change in name or
41 address and submit a fifty dollar (\$50.00) fee to the Department within 15
42 days after the change occurs. A designated caregiver who fails to notify the
43 Department of any of these changes within the specified time frame commits
44 an infraction and is subject to a fine not to exceed one hundred dollars
45 (\$100.00).

46 (3) When a qualified patient or designated caregiver notifies the Department of
47 any change, as required by this subsection, the Department shall issue the
48 qualified patient and each designated caregiver a new registry identification
49 card within 10 days after receiving the updated information and the fifty dollar
50 (\$50.00) fee.

1 (4) When a qualified patient who possesses a registry identification card notifies
2 the Department of a change in designated caregiver, the Department shall
3 notify the designated caregiver of record of the change within 15 days after
4 receiving notification of the change. The protections afforded under this
5 Article to the designated caregiver of record shall expire 30 days after the
6 designated caregiver of record is notified by the Department of the change in
7 designated caregiver.

8 (5) If a qualified patient or a designated caregiver loses a registry identification
9 card, the cardholder shall notify the Department within 15 days after losing
10 the card. The notification shall include a fifty dollar (\$50.00) replacement fee
11 for a new card. Within five days after receiving notification of a lost registry
12 identification card, the Department shall issue the cardholder a new registry
13 identification card with a new random identification number.

14 (g) Suspensions or Revocations. – If the Department determines that a qualified patient
15 or designated caregiver has violated any provision of this Article, the Department shall suspend
16 or revoke the qualified patient's or designated caregiver's registry identification card. Suspensions
17 or revocations may be appealed by filing a contested case petition under Article 3 of Chapter
18 150B of the General Statutes.

19 (h) Rules. – The North Carolina Medical Care Commission shall adopt rules to
20 implement the provisions of this section. The rules shall establish requirements for the issuance
21 of registry identification cards to qualified patients and designated caregivers, which shall include
22 at least all of the following:

23 (1) The method of demonstrating written certification, as defined in
24 G.S. 90-113.112.

25 (2) The amount of the initial or renewal application fee, which shall not exceed
26 fifty dollars (\$50.00) per application or renewal application.

27 (3) The name, address, and date of birth of the qualified patient.

28 (4) The name, address, and telephone number of the qualified patient's physician.

29 (5) The name, address, and date of birth of each of the qualified patient's
30 designated caregivers, if any.

31 (6) A limitation on the number of written certifications a physician may issue at
32 any given time.

33 **§ 90-113.116. Requirement to carry and disclose registry identification card to law**
34 **enforcement.**

35 (a) Requirement to Carry. – A registry identification cardholder shall carry the registry
36 identification card together with valid identification whenever the registry identification
37 cardholder is carrying cannabis or cannabis-infused product as provided in this Article.

38 (b) Requirement to Disclose. – The registry identification cardholder shall disclose to any
39 law enforcement officer that the registry identification cardholder holds a valid registry
40 identification card when approached or addressed by the officer and shall display both the registry
41 identification card and valid identification at the request of a law enforcement officer.

42 **§ 90-113.117. Confidential Medical Cannabis Registry Database.**

43 (a) Confidential Medical Cannabis Registry Database. – The Department shall create a
44 secure, confidential, electronic medical cannabis registry database of all qualified patients and
45 designated caregivers to whom the Department has issued registry identification cards. Law
46 enforcement agencies may contact the Department to confirm registry identification cardholders.
47 The Department shall monitor the medical cannabis registry database and in the event that the
48 Department finds patterns of written certifications that are unusual, the Department shall inform
49 the Attorney General's Office of its findings. The Office of the Attorney General shall review the
50 Department's findings to determine if the findings should be reported to the State Bureau of

1 Investigation and the appropriate sheriff for investigation of possible violations of State or federal
2 law. The database shall consist of at least the following information:

3 (1) The name and address of the registry identification cardholder.

4 (2) The name, address, and hospital affiliation of the physician who issued the
5 written certification of the qualified patient's debilitating condition.

6 (3) A photograph of the registry identification cardholder.

7 (b) Confidential Nature of Information Collected by Department. – Applications and
8 supporting information submitted by qualified patients, including information regarding their
9 designated caregivers and physicians, individual names, and other identifying information in the
10 medical cannabis registry database, are confidential, exempt from the provisions of Chapter 132
11 of the General Statutes, and are not subject to disclosure, except to authorized employees of the
12 Department as necessary to perform official duties of the Department and law enforcement
13 agencies as allowed in subsection (h) of this section.

14 (c) Penalty for Confidentiality Breaches. – Any person, including an employee or official
15 of the Department or another State agency or local government, who breaches the confidentiality
16 of information obtained pursuant to this section is guilty of a Class 2 misdemeanor; however,
17 any fine imposed for a violation under this subsection shall not exceed one thousand dollars
18 (\$1,000).

19 (d) Reports of Falsified or Fraudulent Application Information to Law Enforcement
20 Personnel. – Nothing in this section shall be construed to prevent Department employees from
21 notifying law enforcement personnel about falsified or fraudulent information submitted to the
22 Department by any individual in support of an application for a registry identification card.

23 **"§ 90-113.118. Medical Cannabis Production Commission.**

24 (a) Commission Established. – The Medical Cannabis Production Commission is
25 established and shall consist of 11 members as follows:

26 (1) The Governor shall appoint members to the Medical Cannabis Production
27 Commission as follows:

28 a. A qualified patient representative.

29 b. Two industry representatives, subject to the limitation that, although
30 the industry representatives may participate in assisting with the
31 process of adopting rules, the industry representatives must not
32 participate in the license selection process if the industry
33 representatives have applied for or have an affiliation with a medical
34 cannabis supplier license applicant through family or business.

35 (2) The Secretary of the Department, or designee.

36 (3) The Director of the North Carolina State Bureau of Investigation, or designee.

37 (4) The Agriculture Commissioner, or designee.

38 (5) A sheriff designated by the North Carolina Sheriffs' Association.

39 (6) A chief of police designated by the North Carolina Association of Chiefs of
40 Police.

41 (7) A physician member of the North Carolina Medical Board designated by the
42 North Carolina Medical Board.

43 (8) A member appointed by the General Assembly upon recommendation of the
44 Speaker of the House of Representatives in accordance with G.S. 120-121.

45 (9) A member appointed by the General Assembly upon recommendation of the
46 President Pro Tempore of the Senate in accordance with G.S. 120-121.

47 (b) Terms. – Members of the Commission shall serve terms of four years, beginning
48 effective July 1 of the year of appointment, and may be reappointed to a second four-year term.
49 The terms of members designated by subdivisions (a)(1), (a)(2), and (a)(4) of this section shall
50 expire on June 30 of any year evenly divisible by four. The terms of the remaining members shall
51 expire on June 30 of any year that follows by two years a year evenly divisible by four.

1 (c) Chair. – The members of the Commission shall elect a chair. The chair shall serve a
2 two-year term and may be reelected.

3 (d) Vacancies. – Any appointment to fill a vacancy on the Commission created by the
4 resignation, dismissal, death, or disability of a member shall be made by the original appointing
5 authority and shall be for the balance of the unexpired term.

6 (e) Removal. – The appointing authority shall have the power to remove any member of
7 the Commission appointed by that authority from office for misfeasance, malfeasance, or
8 nonfeasance.

9 (f) Expenses. – The members of the Commission shall receive per diem and necessary
10 travel and subsistence expenses in accordance with the provisions of G.S. 138-5.

11 (g) Quorum. – Five members of the Commission shall constitute a quorum for the
12 transaction of business.

13 (h) Licensing Power. – The Commission shall have the power to approve applications for
14 medical cannabis supplier licenses upon recommendation of the Department by a majority vote
15 of the members present and voting. The Department shall evaluate the applications in accordance
16 with G.S. 90-113.120 and submit a list of 20 recommended applicants to the Commission. The
17 Commission shall approve 10 licenses from the list by a majority vote of the members present
18 and voting. In awarding the licenses, the Commission shall require each supplier own and operate
19 no more than four medical cannabis centers. Of the medical cannabis centers operated by each
20 supplier, at least two shall be located in Tier 1 counties.

21 (i) License Suspension or Revocation. – The Commission may suspend or revoke a
22 medical cannabis supplier license if the Commission determines that the supplier is not in
23 substantial compliance with this Chapter or with rules adopted by the Commission under
24 subsection (k) of this section. The Department shall notify a supplier at least 14 days in advance
25 of a proposed suspension or revocation, including the reasons for the suspension or revocation
26 and any possible remedial options available to the supplier. The Commission has the power to
27 administer oaths and issue subpoenas to require the presence of persons and the production of
28 papers, books, and records necessary to conduct a suspension or revocation hearing. The
29 suspension or revocation may be appealed by filing a contested case petition under Article 3 of
30 Chapter 150B of the General Statutes.

31 (j) All administrative support and other services required by the Commission shall be
32 provided by the Department.

33 (k) Rules. – The Commission, in consultation with the North Carolina Medical Care
34 Commission, shall adopt rules to implement the provisions of this section, G.S. 90-113.119,
35 90-113.120, 90-113.121, and 90-113.122. The rules shall do all of the following:

36 (1) Establish qualifications and requirements for licensure of suppliers, for the
37 production of cannabis by a supplier, and for the proper regulation of medical
38 cannabis centers and production facilities operated by suppliers.

39 (2) Ensure the equitable distribution of medical cannabis centers throughout the
40 State in order for registry identification cardholders to access an adequate
41 supply of cannabis and cannabis-infused products, while preventing an
42 overconcentration of medical cannabis centers in any one area.

43 (3) Establish civil penalties for minor violations of the requirements of this
44 Chapter and rules adopted under the authority provided in this subsection.

45 **"§ 90-113.119. Regulated medical cannabis supply system.**

46 (a) Medical Cannabis Supply System. – The Medical Cannabis Production Commission
47 established in G.S. 90-113.118 shall establish a medical cannabis supply system that authorizes
48 suppliers to produce cannabis and cannabis-infused products in licensed cannabis products
49 facilities and distribute them through medical cannabis centers. In establishing the medical
50 cannabis supply system, the Commission shall (i) provide a safe, regulated supply of cannabis
51 appropriate for medical use by qualified registry identification cardholders issued under

1 G.S. 90-113.115, (ii) ensure statewide access to safe and affordable cannabis to registry
2 identification cardholders, (iii) establish a system that is well-regulated, includes a seed-to-sale
3 tracking system, and is financially viable for suppliers to ensure the highest quality cannabis and
4 cannabis-infused products for patients, and (iv) generate sufficient revenue for the Commission
5 to oversee and for the Department to maintain and operate the system.

6 (b) Funding. – The General Assembly may appropriate funds for the initial development
7 and implementation of the medical cannabis supply system, but neither the Department nor the
8 Commission shall use any appropriations from the General Fund to operate the system. The intent
9 of the General Assembly is that the system shall be funded solely by the fees authorized in this
10 Article.

11 **"§ 90-113.120. Medical cannabis supplier license.**

12 (a) Definitions. – The following definitions apply in this section:

13 (1) Nonresident business. – An entity that has not been required to file an income
14 or franchise tax return with the State for three years prior to filing an initial
15 application for a medical cannabis supplier license that meets one or more of
16 the following conditions:

17 a. Is a nonresident entity.

18 b. Is a nonresident individual who owns an unincorporated business as a
19 sole proprietor.

20 (2) Nonresident entity. – Defined in G.S. 105-163.1.

21 (3) Nonresident individual. – Defined in G.S. 105-153.3.

22 (b) Prohibitions. – No person shall do any of the following without first obtaining a
23 medical cannabis supplier license from the Commission:

24 (1) Grow, cultivate, produce, or sell cannabis or cannabis-infused products.

25 (2) Operate a business to produce cannabis or cannabis-infused products.

26 (3) Establish or operate a medical cannabis center for the sale of cannabis,
27 cannabis-infused products, and paraphernalia relating to the administration of
28 cannabis to qualified patients and designated caregivers who hold valid
29 registry identification cards.

30 (c) Medical Cannabis Supplier License Application; Fees. – An applicant for a license
31 under this subsection shall submit the required information on application forms provided by the
32 Department. The application form shall require at least all of the following:

33 (1) The applicant's name and any legal names the applicant will use for facilities
34 where the applicant will produce cannabis and for each medical cannabis
35 center and production facility the applicant proposes to operate.

36 (2) The address of each property, location, or premises the applicant will use to
37 produce cannabis, of each production facility the applicant will use to process
38 cannabis or produce cannabis-infused products, and of each medical cannabis
39 center the applicant will use to dispense or distribute cannabis.

40 (3) Documentation demonstrating that the applicant possesses:

41 a. Requisite expertise in controlled environment agriculture and at least
42 five years of experience in cultivation, production, extraction, product
43 development, quality control, and inventory management of medical
44 cannabis in a state-licensed medical or adult use cannabis operation
45 meeting standards that the Commission shall specify by rule.

46 b. Significant technical and technological ability to cultivate, produce,
47 and distribute medical cannabis in a manner that meets industry
48 standards for production consistency and safe handling.

49 c. Relevant experience in securing cannabis production, testing,
50 resources, transportation, and personnel to operate as a safe and secure

- 1 supplier in compliance with all state regulations in which the applicant
2 has prior experience.
- 3 (4) Proposed operating procedures for each production facility, medical cannabis
4 center, and component of the applicant's proposed medical cannabis supply
5 system, including record keeping and security requirements as the
6 Commission shall specify by rule.
- 7 (5) The name, address, and date of birth of each principal officer and board
8 member of the supplier.
- 9 (6) The name, address, and date of birth of each employee of the supplier.
- 10 (7) For first-year suppliers, a nonrefundable license fee in the amount of fifty
11 thousand dollars (\$50,000) plus five thousand dollars (\$5,000) for each
12 production facility or medical cannabis center the applicant proposes to
13 operate under the license.
- 14 (8) For suppliers seeking license renewal, a nonrefundable renewal fee in an
15 amount not less than ten thousand dollars (\$10,000) plus one thousand dollars
16 (\$1,000) for each production facility or medical cannabis center the supplier
17 operates under the license as specified in rules adopted by the Commission
18 pursuant to G.S. 90-113.118 and annual audited financial statements audited
19 by an independent certified public accountant.
- 20 (9) Proof the applicant has been a State resident for at least two years and will be
21 the majority owner of each medical cannabis center and production facility
22 the applicant proposes to operate. The applicant may include nonresident
23 partners with demonstrated ownership and operation experience in the
24 cultivation, production, extraction, product development, quality control, and
25 inventory management of cannabis products in a state-licensed medical or
26 adult use cannabis operation and shall provide proof of state residency for any
27 nonresident partner of the applicant.
- 28 (10) The name, address, and date of birth of any individual owning more than five
29 percent (5%) of the medical cannabis center and production facility the
30 supplier operates.
- 31 (11) Proof in a manner and amount as the Commission shall specify by rule that
32 the applicant has sufficient liquid and nonliquid assets to operate as a supplier
33 for two years as a part of the medical cannabis supply system established by
34 this Article.
- 35 (12) Any other information the Department considers necessary to ensure
36 compliance with the terms of this Article.
- 37 (d) Duration. – Unless suspended or revoked, a medical cannabis supplier license is valid
38 for a period not to exceed 12 months from the date of issuance.
- 39 (e) Renewal. – A supplier shall apply for renewal, as necessary, at least 30 days prior to
40 the expiration of a current license.
- 41 (f) Time Frame for Issuance; Fees. – No later than 30 days after issuing or renewing a
42 license under this subsection, the Department shall issue a supplier registry identification card to
43 each director and employee listed on the application or renewal form upon receipt of a two
44 hundred fifty dollar (\$250.00) fee per cardholder.
- 45 (g) Notification of Changes. – An applicant or supplier shall notify the Department of
46 any change in the information submitted on the license application or renewal form within 30
47 days after the change.
- 48 (h) Availability of Records. – The records of a medical cannabis center operated by a
49 supplier are subject to the same restrictions imposed on pharmacy records pursuant to
50 G.S. 90-85.36. G.S. 90-85.36 applies to each medical cannabis center as if it were a pharmacy
51 regulated under Article 4A of Chapter 90 of the General Statutes.

1 (i) Cannabis Production Site Card. – The Department shall issue a cannabis production
2 site card to each supplier for each production facility approved under this section. The card shall
3 be posted conspicuously at each production facility.

4 (j) Performance Requirements. – A supplier must begin cultivation of cannabis within
5 120 days of receiving a medical cannabis supplier license and begin selling cannabis and
6 cannabis-infused products in medical cannabis centers within 180 days of initiating cultivation.

7 (k) Criminal History Record Check. – In order to ensure compliance with this section,
8 the Department shall conduct a criminal history record check of any person whose name is
9 submitted on an application as an owner, director, or an employee of the supplier. When
10 requested by the Department, the North Carolina Department of Public Safety may provide to
11 the Department a person's criminal history from the State Repository of Criminal Histories. Such
12 requests shall not be due to a person's age, sex, race, color, national origin, religion, creed,
13 political affiliation, or handicapping condition as defined in G.S. 168A-3. For requests for a State
14 criminal history record check only, the Department shall provide to the Department of Public
15 Safety a form consenting to the check signed by the person to be checked and any additional
16 information required by the Department of Public Safety. National criminal record checks are
17 authorized for applicants who have not resided in the State of North Carolina during the past five
18 years. For national checks, the Department shall provide to the North Carolina Department of
19 Public Safety the fingerprints of the person to be checked, any additional information required
20 by the Department of Public Safety, and a form signed by the person to be checked consenting
21 to the check of the criminal record and to the use of fingerprints and other identifying information
22 required by the State or National Repositories. The fingerprints of the individual shall be
23 forwarded to the State Bureau of Investigation for a search of the State criminal history record
24 file, and the State Bureau of Investigation shall forward a set of fingerprints to the Federal Bureau
25 of Investigation for a national criminal history record check. The Department of Health and
26 Human Services shall keep all information pursuant to this section confidential. The Department
27 of Public Safety shall charge a reasonable fee for conducting the checks of the criminal history
28 records authorized by this section. All releases of criminal history information to the Department
29 shall be subject to, and in compliance with, rules governing the dissemination of criminal history
30 record checks as adopted by the North Carolina Department of Public Safety. All of the
31 information either department receives through the checking of the criminal history is privileged
32 information and for the exclusive use of that department.

33 (l) Duty to Update. – In order to continue to hold a license under this Article, a supplier
34 shall notify the Commission of any change in criminal history of any person required to be
35 evaluated by the Department under this section. The Commission may reevaluate the supplier's
36 eligibility for a license based on the notification and may modify or revoke the license or require
37 issuance of a new license with appropriate terms to exclude disqualifying persons.

38 (m) Disqualifications for Licensure. – The Commission shall not issue a license
39 authorized by this section to any of the following persons:

40 (1) A person who has not paid the appropriate license or license renewal fee.

41 (2) An individual who is less than 21 years of age.

42 (3) A person who has served a sentence for any of the following felonies in the
43 five years immediately preceding the date of license application: any Class A
44 through E felony; any felony that includes assault as an essential element of
45 the offense; any felony under Article 14 (Burglary and Other Housebreakings)
46 of Chapter 14 of the General Statutes; any felony under Article 16 (Larceny),
47 Article 16A (Organized Retail Theft), Article 17 (Robbery), Article 18
48 (Embezzlement), Article 19 (False Pretenses and Cheats), Article 19A
49 (Obtaining Property or Services by False or Fraudulent Use of Credit Device
50 or Other Means), Article 19B (Financial Transaction Card Crime Act), or
51 Article 19C (Financial Identity Theft) of Chapter 14 of the General Statutes.

1 (4) A person (or, with respect to a person who is not an individual, an owner,
2 director, or employee of the person) who at any time has been convicted of a
3 felony violation for manufacturing, selling, delivering, or possessing with
4 intent to manufacture, sell, deliver, or possess a Schedule I or II controlled
5 substance, in violation of G.S. 90-95(b)(1).

6 (5) Except as otherwise provided in this subdivision, a person who has not been
7 a resident of North Carolina for at least two years prior to the date of the
8 license application, unless that person is a minority partner of a State resident
9 who is the majority owner of the applicant. With respect to a person who is
10 not an individual, a person that is a nonresident business.

11 (n) Administrative and Judicial Review. – Articles 3 and 4 of Chapter 150B of the
12 General Statutes govern administrative and judicial review of an administrative decision made
13 under this section.

14 **"§ 90-113.121. Restrictions on supplier sales and supply.**

15 (a) Restrictions on Sales and Supply. – A person licensed as a supplier under this Article
16 is subject to the following sales and supply restrictions:

17 (1) The supplier may sell cannabis and cannabis-infused products only through
18 the medical cannabis center that the supplier is licensed to operate under this
19 section. A medical cannabis center shall not sell cannabis, cannabis-infused
20 products, or paraphernalia relating to the administration of cannabis to any
21 person other than a qualified patient, designated caregiver, or except as
22 provided in subdivision (3) of this subsection. A medical cannabis center shall
23 not sell cannabis or cannabis-infused products in an amount that exceeds an
24 adequate supply to any qualified patient or designated caregiver.

25 (2) The supplier may sell only cannabis grown by the supplier at the production
26 facilities approved under this section. Except as provided in subdivision (3) of
27 this subsection, the supplier shall not sell cannabis, cannabis plants, cannabis
28 seeds, or cultivation equipment to any other person other than through the
29 medical cannabis center that the supplier is licensed to operate.

30 (b) Resale. – The supplier may sell cannabis or cannabis-infused products for resale to
31 another licensed supplier.

32 **"§ 90-113.122. Supplier reporting; monthly fees.**

33 (a) Quarterly Reports. – Each supplier licensed under this Article shall submit quarterly
34 reports to the Department on all financial transactions, including, but not limited to, production,
35 sales and purchases of cannabis and cannabis-infused products, and transfers of cannabis and
36 cannabis-infused products for no consideration with respect to each medical cannabis center and
37 production facility operated by the supplier.

38 (b) Monthly Fee. – Each supplier licensed under this section shall pay to the Department
39 a monthly fee equal to ten percent (10%) of the gross revenue derived from the sale of cannabis
40 and cannabis-infused products at all medical cannabis centers operated by the supplier.

41 (c) Construction. – Nothing in this section shall be construed to exempt persons licensed
42 under this section from the reporting or remittance of sales tax for any transaction upon which a
43 sales tax may be levied.

44 **"§ 90-113.123. Exemption from criminal laws.**

45 (a) Exemption from Criminal Laws. – A supplier is exempt from the criminal laws of this
46 State for possession, production, delivery, or transportation of cannabis or aiding and abetting
47 another in the possession, production, delivery, or transportation of cannabis or any other
48 criminal offense in which possession, production, delivery, or transportation of cannabis is an
49 element if the individual is in compliance with this Article and rules adopted under this Article.

50 (b) Loss of Exemption from Criminal Laws. – A person who is not a qualified patient or
51 a designated caregiver but who is otherwise authorized to possess, produce, deliver, or transport

1 cannabis for medical use pursuant to this Article ceases to be exempt as provided in subsection
2 (a) of this section upon committing any of the following acts:

- 3 (1) Driving while impaired in violation of G.S. 20-138.1, 20-138.2, or 20-138.5.
- 4 (2) Delivering cannabis to any individual who the person knows or has reason to
5 know is not a qualified patient or designated caregiver who holds a valid
6 registry identification card issued under G.S. 90-113.115, or a supplier who
7 holds a license under G.S. 90-120.
- 8 (3) Manufacturing or distributing cannabis at an address not registered with the
9 Department.
- 10 (4) Failing to report transfer of cannabis authorized under this Article to the
11 Department.

12 **"§ 90-113.124. Protections for the medical use of cannabis.**

13 (a) A registry identification cardholder shall not be subject to arrest, prosecution, or
14 penalty in any manner for the possession or purchase of cannabis for medical use by the qualified
15 patient if the quantity of usable cannabis possessed or purchased does not exceed an adequate
16 supply, as determined by the qualified patient's physician.

17 (b) If usable cannabis is infused or added as an ingredient to an edible cannabis product,
18 salve, tincture, or any other preparation to be consumed or used by a qualified patient, the weight
19 of the other ingredients that are not usable cannabis shall not be included for the purpose of
20 determining whether a qualified patient is in possession of an amount of cannabis that exceeds
21 the qualified patient's adequate supply.

22 (c) A supplier shall not be subject to arrest, prosecution, or penalty in any manner for
23 producing, possessing, distributing, or dispensing cannabis or cannabis-infused products in a
24 manner consistent with this Article.

25 (d) When an employee, officer, or agent of the State makes a finding, determination, or
26 otherwise considers a qualified patient or designated caregiver's possession or use of cannabis,
27 or a cannabis-infused product, the employee, officer, or agent may not consider the qualified
28 patient or designated caregiver's possession or use any differently than the lawful possession or
29 use of any prescribed controlled substance, if the qualified patient or designated caregiver's
30 possession or use complies with this Article.

31 (e) Nothing in this Article shall be construed to extend the protections of this Article to
32 any person, including a qualified patient, a designated caregiver, or a supplier, to allow that
33 person to acquire, possess, manufacture, produce, use, sell, distribute, dispense, or transport
34 cannabis in a manner that is not consistent with this Article.

35 **"§ 90-113.125. Smoking and vaping prohibited in certain places.**

36 (a) Nothing in this Article shall authorize a registry identification cardholder to engage
37 in the smoking of cannabis or the vaping of cannabis for medical use in the following places:

- 38 (1) In a public place or a place open to the public.
- 39 (2) In any place of employment.
- 40 (3) In a vehicle.
- 41 (4) In or within 1,000 linear feet of the property line of a church, unless the
42 medical use occurs within a private residence.
- 43 (5) In or within 1,000 linear feet of the property line of a child care facility as
44 defined in G.S. 110-86(3), unless the medical use occurs within a private
45 residence. When a private residence is a child care facility, the smoking of
46 cannabis and the vaping of cannabis is prohibited.
- 47 (6) In or within 1,000 linear feet of the property line of a public school unit or any
48 nonpublic school as defined in Part 1 or Part 2 of Article 39 of Chapter 115C
49 of the General Statutes, unless the medical use occurs within a private
50 residence.

1 (7) In or within 1,000 linear feet of the property line of a community college or
2 the facilities of The University of North Carolina and the grounds of those
3 facilities as defined in G.S. 143-597(a)(6), unless the medical use occurs
4 within a private residence. Smoking or vaping is permitted inside buildings
5 that are used for medical or scientific research to the extent that smoking or
6 vaping is an integral part of the research. Smoking or vaping permitted under
7 this subdivision shall be confined to the area where the research is being
8 conducted.

9 (b) Any individual who engages in the smoking of cannabis or the vaping of cannabis in
10 violation of this section shall be guilty of an infraction and punished by a fine of not more than
11 twenty-five dollars (\$25.00).

12 **"§ 90-113.126. Violations; penalties; and enhanced sentence for trafficking related to**
13 **medical cannabis.**

14 (a) Any person who manufactures, sells, delivers, or possesses with intent to
15 manufacture, sell, or deliver cannabis in violation of this Article at a medical cannabis center or
16 production facility shall be punished as a Class G felon.

17 (b) Any person who creates, sells, delivers, or possesses with intent to sell or deliver
18 counterfeit cannabis in violation of this Article at a medical cannabis center or production facility
19 shall be punished as a Class H felon.

20 (c) Any person who possesses an amount of cannabis up to 1 1/2 ounces in violation of
21 this Article, at a medical cannabis center or production facility, shall be deemed guilty of a Class
22 A1 misdemeanor.

23 (d) Any person who possesses an amount of cannabis that exceeds 1 1/2 ounces in
24 violation of this Article, at a medical cannabis center or production facility, shall be punished as
25 a Class H felon.

26 (e) Any person that provides the Department with false or misleading information in
27 relation to a registry identification card or license shall be deemed guilty of a Class 1
28 misdemeanor.

29 (f) Any person who has been issued a valid registry identification card who is found to
30 be in possession of cannabis in violation of this Article shall be punished as a Class I felon.

31 (g) If a person is convicted of a violation of G.S. 90-95(h)(1), and it is found that the
32 offense was committed at a medical cannabis center or production facility or with cannabis from
33 a medical cannabis center or production facility, then the person shall be sentenced at a felony
34 class level one class higher than the principal felony for which the person was convicted, and an
35 additional 12 months will be added to the mandatory minimum sentence. No defendant sentenced
36 pursuant to this section shall be sentenced at a level higher than a Class C felony. An indictment
37 or information for the felony shall allege in that indictment or information the facts that qualify
38 the offense for an enhancement under this section. One pleading is sufficient for all felonies that
39 are tried at a single trial.

40 (h) These penalties may be imposed in addition to any other penalties provided by law.

41 **"§ 90-113.127. North Carolina medical cannabis verification system.**

42 (a) Verification System. – The Department shall establish a secure web-based
43 verification system. The verification system shall allow authorized Department personnel, State
44 and local law enforcement personnel, and medical cannabis centers to enter a registry
45 identification card number to determine whether the number corresponds with a current, valid
46 registry identification card. For the purposes of this subsection, the system may disclose only:

47 (1) Whether the registry identification card is valid.

48 (2) The name, address, and date of birth of the cardholder.

49 (3) A photograph of the cardholder, if required by Department rules.

50 (4) Whether the cardholder is a qualifying patient or a designated caregiver.

- 1 (5) The registry identification card number of any associated qualifying patients
2 or designated caregivers.
- 3 (6) Only if accessed by a medical cannabis center employee or authorized
4 Department personnel, the amount of cannabis and cannabis-infused products
5 dispensed in the past 30 days.
- 6 (7) The delivery method of the cannabis.
- 7 (b) Verification System Access. – No person or entity may have access to information
8 contained in the Department's verification system, except for an authorized employee of the
9 Department in the course of official duties or a State or local law enforcement officer in the
10 course of official duties related to a person who claims to be a qualifying patient, designated
11 caregiver, supplier, or supplier agent engaged in conduct authorized in this Article.
- 12 (c) Requirement to Check. – Before cannabis or cannabis-infused products may be
13 dispensed to a registry identification cardholder, a medical cannabis center employee shall access
14 the verification system and determine that:
- 15 (1) The registry identification card presented at the medical cannabis center is
16 valid.
- 17 (2) Each person presenting a registry identification card is the person identified
18 on the registry identification card presented to the medical cannabis center
19 employee.
- 20 (3) The amount to be dispensed would not cause a qualifying patient, directly or
21 via the qualifying patient's designated caregiver, to exceed the limit on
22 obtaining no more than an adequate supply of cannabis or cannabis-infused
23 products during any 30-day period.
- 24 (4) The cannabis to be dispensed complies with the delivery method.
- 25 (5) After making the determinations required in subdivisions (3) and (4) of this
26 subsection, but before dispensing cannabis or cannabis-infused products to a
27 registry identification cardholder, a medical cannabis center employee shall
28 enter the following information in the verification system:
- 29 a. How much cannabis or cannabis-infused product is to be dispensed to
30 the registry identification cardholder.
- 31 b. Whether the cannabis or cannabis-infused product is to be dispensed
32 directly to the qualifying patient or to the qualifying patient's
33 designated caregiver.
- 34 c. The date and time the cannabis or cannabis-infused product is to be
35 dispensed.
- 36 d. The registry identification number of the medical cannabis center that
37 dispensed the cannabis or cannabis-infused product.

38 **§ 90-113.128. Inspections; security measures.**

39 (a) Inspection. – The Department shall perform annual inspections of the premises of any
40 person licensed under this section, including any production facility or medical cannabis center.
41 All production facilities and medical cannabis centers owned and operated by a supplier are
42 subject to random inspection by the Department, and the North Carolina State Bureau of
43 Investigation in accordance with rules adopted by the Commission, which shall be developed by
44 the Commission after consulting with and receiving input from the North Carolina State Bureau
45 of Investigation.

46 (b) Security Measures. –

- 47 (1) Suppliers shall implement appropriate security measures in accordance with
48 rules adopted by the Commission, which shall be developed by the
49 Commission after consulting with and receiving input from the North Carolina
50 State Bureau of Investigation, designed to deter and prevent the theft of

1 cannabis and cannabis-infused products and unauthorized entrance into areas
2 containing cannabis or cannabis-infused products.

- 3 (2) All production facilities shall conduct cultivation, harvesting, processing, and
4 packaging of cannabis and cannabis-infused products in a controlled, secure
5 facility at a physical address provided to the Commission during the medical
6 cannabis supplier license application process. A production facility may only
7 be accessed by a supplier or a supplier's employee or agent, authorized
8 Department personnel, law enforcement personnel, emergency personnel, and
9 adults who are 21 years of age and older who are accompanied by a supplier
10 or supplier's agents or principals.

11 **"§ 90-113.129. Medical cannabis center hours; location and age restrictions.**

12 (a) Hours. – A medical cannabis center licensed under this Article shall not sell cannabis
13 or cannabis-infused products between the hours of 7:00 P.M. and 7:00 A.M.

14 (b) Location. – A medical cannabis center shall not be located within 1,000 linear feet of
15 the property line of any of the following places:

16 (1) A church.

17 (2) A child care facility as defined in G.S. 110-86(3).

18 (3) A public school unit or any nonpublic school as defined in Part 1 or Part 2 of
19 Article 39 of Chapter 115C of the General Statutes.

20 (4) A community college or the facilities of The University of North Carolina and
21 the grounds of those facilities as defined in G.S. 143-597(a)(6).

22 (c) Age. – An individual must be 18 years old or older to enter a medical cannabis center,
23 unless the individual is a registry identification cardholder.

24 **"§ 90-113.130. Testing of cannabis and cannabis-infused products.**

25 (a) The Department shall establish standards for and shall license up to five independent
26 testing laboratories to test cannabis and cannabis-infused products that are to be sold in the State.
27 An independent testing laboratory shall analyze a representative sample of all cannabis or
28 cannabis-infused products before the sale or transfer to a medical cannabis center by a production
29 facility. An independent testing laboratory shall report the results of all testing required by the
30 Department to the Department.

31 (b) An independent testing laboratory shall be responsible for selecting, picking up, and
32 testing product samples.

33 (c) The Department shall adopt rules to establish, at a minimum, the following:

34 (1) Standards for testing cannabis and cannabis products, including specifying
35 prohibited concentrations of heavy metals, pesticides, microbes, and other
36 contaminants that are injurious to human health.

37 (2) Standards for independent testing laboratories, including requirements for
38 equipment and qualifications for personnel.

39 (3) Standards and requirements necessary for an independent testing laboratory
40 to be licensed.

41 (4) Remedial actions to be taken if the representative sample does not meet the
42 standards established by the Department.

43 (5) A fee schedule for independent testing laboratories.

44 **"§ 90-113.131. Advertising.**

45 (a) The production facility or medical cannabis center logo, signage, and advertising shall
46 be tasteful, respectful, and medically focused and shall not appeal to minors or contain
47 cartoon-like figures or attempts at humor. Suppliers are prohibited from using marijuana leaves
48 or slang for cannabis or cannabis-infused products in or on their logos, packaging, or structures.
49 Suppliers may not use neon-colored signage, logos, or packaging or neon-colored signage or
50 logos on structures. The supplier shall submit any logo or sign for review to the Department in
51 accordance with Department rules.

1 **(b) Notwithstanding any municipal or county ordinance prohibiting signage, the medical**
2 **cannabis center shall only use signage that includes the medical cannabis center's name, logo,**
3 **and hours of operation.**

4 **(c) A medical cannabis center may maintain a website that includes information about:**

5 **(1) The location and hours of operation of the medical cannabis center.**

6 **(2) The product or service available at the medical cannabis center.**

7 **(3) The personnel affiliated with the medical cannabis center.**

8 **(4) The best practices that the medical cannabis center upholds.**

9 **(5) Educational material related to the medical use of cannabis, as defined by the**
10 **Department.**

11 **(d) All production facilities and medical cannabis centers owned and operated by a**
12 **supplier shall maintain a discreet, professional appearance that is compatible with existing**
13 **commercial structures or land uses within the immediate area, including requirements to maintain**
14 **the production facility or medical cannabis center in a manner to prevent blight, deterioration,**
15 **diminishment, or impairment of property values within the vicinity.**

16 **(e) The Department shall adopt rules to define standards for a medical cannabis center's**
17 **name, signage, and logo to ensure a medical rather than recreational disposition.**

18 **"§ 90-113.132. Packaging of cannabis and cannabis-infused products.**

19 **(a) Definitions. – The following definitions apply in this section:**

20 **(1) Child-resistant packaging. – A package that is designed or constructed to be**
21 **significantly difficult for children under 5 years of age to open and not difficult**
22 **for normal adults to use properly, substantially similar to those defined by 16**
23 **C.F.R. § 1700.20 (1995), opaque so that the packaging does not allow the**
24 **product to be seen without opening the packaging material, and resealable for**
25 **any product intended for more than a single use or containing multiple**
26 **servings.**

27 **(2) Exit packaging. – A sealed, child-resistant packaging receptacle into which**
28 **pre-packaged cannabis products are placed at the retail point of sale at a**
29 **medical cannabis center.**

30 **(b) Suppliers shall safely package and accurately label cannabis or cannabis-infused**
31 **products. All items sold at a medical cannabis center shall be properly labeled and contained in**
32 **child-resistant packaging. Labels shall not include strain names but may include cannabinoid and**
33 **terpene profiles for identification. Each label shall comply with State laws and rules and, at a**
34 **minimum, shall include:**

35 **(1) The name of the medical cannabis center.**

36 **(2) The percentage of tetrahydrocannabinol and the percentage of cannabidiol**
37 **within a profile tolerance range of ten percent (10%). For edible cannabis**
38 **products, the cannabinoid profile should be listed by milligrams per serving.**

39 **(3) The name of the production facility.**

40 **(4) A conspicuous statement printed in all capital letters and in a color that**
41 **provides a clear contrast to the background that reads, "NOT FOR RESALE.**
42 **FOR MEDICAL USE ONLY. KEEP OUT OF THE REACH OF CHILDREN**
43 **AND ANIMALS."**

44 **(5) The length of time it typically takes for the product to take effect.**

45 **(6) For edible cannabis-infused products, the disclosure of ingredients, possible**
46 **allergens, nutritional fact panel, and a standard symbol indicating that the**
47 **product contains cannabis.**

48 **(c) All cannabis products purchased in medical cannabis centers shall be placed in**
49 **child-resistant exit packaging before leaving the medical cannabis center.**

50 **(d) The Department shall adopt rules to do, at a minimum, all of the following:**

- 1 (1) Establish requirements and procedures for the safe, appropriate, and accurate
2 packaging and labeling of cannabis and cannabis-infused products for human
3 consumption, including prohibiting the use of any images designed or likely
4 to appeal to minors, including cartoons, toys, animals, or children, any other
5 likeness to images, characters, or phrases that are popularly used to advertise
6 to children, or any imitation of candy packaging or labeling.
7 (2) Establish requirements to ensure that cannabis and cannabis-infused products
8 for human consumption are designed, marketed, and packaged in a manner
9 that is appropriate for a medicinal product and that does not resemble
10 commercially sold candies or other food that is typically marketed to children.
11 (3) Establish restrictions on the forms and appearance of edible cannabis-infused
12 products in order to reduce their appeal to minors, including prohibiting edible
13 cannabis products in the shapes of cartoons, toys, animals, or people.

14 **"§ 90-113.133. Disposal of cannabis.**

15 (a) All production center cannabis by-product, cannabis scrap, and harvested cannabis
16 not intended for distribution to a medical cannabis center or independent testing laboratory shall
17 be destroyed and disposed of in accordance with Department rules. Documentation of destruction
18 and disposal shall be retained by the production center for a period of not less than one year. The
19 production center shall maintain a record of the date of destruction and the amount destroyed.

20 (b) A medical cannabis center shall destroy all cannabis and cannabis-infused products
21 that are not sold to registry identification cardholders in accordance with Department rules. The
22 medical cannabis center shall retain documentation of the destruction and disposal for a period
23 of not less than one year. The medical cannabis center shall maintain a record of the date of
24 destruction and the amount destroyed.

25 (c) A medical cannabis center shall destroy all unused cannabis products that are returned
26 to the medical cannabis center by a former qualifying patient who no longer qualifies for the use
27 of medical cannabis or the former qualifying patient's caregiver.

28 **"§ 90-113.134. North Carolina Cannabis Research Program.**

29 (a) It is the intent of the General Assembly that The University of North Carolina System
30 undertake objective, scientific research regarding the administration of cannabis or
31 cannabis-infused products as part of medical treatment. The University of North Carolina shall
32 create a program to be known as the North Carolina Cannabis Research Program.

33 (b) The research conducted under this section may involve the development of quality
34 control, purity, and labeling standards for cannabis dispensed through the regulated medical
35 cannabis supply system; sound advice and recommendations on the best practices for the safe
36 and efficient cultivation of cannabis; and analysis of genetic and healing properties of the many
37 varied strains of cannabis to determine which strains may be best suited for a particular condition
38 or treatment.

39 **"§ 90-113.135. Educational campaign.**

40 (a) The Department, in consultation with medical professionals, shall develop an
41 educational campaign about the regulated medical cannabis supply system. The educational
42 campaign shall be regularly advertised through television, online, or social media. The
43 educational campaign must include:

- 44 (1) The debilitating medical conditions which may be treated with medical use.
45 (2) Potential benefits and risks of the use of cannabis and cannabis-infused
46 products.
47 (3) A notification that cannabis and cannabis-infused products are for a qualifying
48 patient's use only and that they should not be donated or otherwise supplied to
49 another individual.

1 (b) The Department shall make the information identified in subsection (a) of this section
2 available online with a link to the information conspicuously located on the Department's
3 website.

4 **"§ 90-113.136. North Carolina Medical Cannabis Program Fund.**

5 There is established within the Department the North Carolina Medical Cannabis Program
6 Fund to ensure the availability of funds necessary to carry out the Department's responsibilities
7 under this Article. All monies collected pursuant to this Article shall be deposited into the Fund.
8 The Fund shall be used for direct and indirect costs associated with the implementation,
9 administration, and enforcement of this Article. Revenues generated in excess of the amount
10 needed to implement, administer, and enforce this Article shall be annually distributed to the
11 State General Fund.

12 **"§ 90-113.137. Self-supporting requirement; use of excess revenue.**

13 (a) Self-Supporting Requirement. – The system revenues from license fees and monthly
14 gross revenue fees are appropriated to the Commission to fund in the following order of priority:

- 15 (1) Costs associated with establishing and operating the regulated medical
16 cannabis supply system established under this section.
- 17 (2) The registry system established under G.S. 90-113.119.
- 18 (3) The North Carolina Cannabis Research Program established under
19 G.S. 90-113.134, limited to an amount of funding to be determined by the
20 Commission.

21 (b) Use of Excess Revenues. – Any revenues remaining at the end of a fiscal year after
22 the Commission fully funds the priorities set forth in subsection (a) of this section shall be
23 transferred at the beginning of the subsequent fiscal year to the General Fund.

24 **"§ 90-113.138.** Reserved for future codification purposes.

25 **"§ 90-113.139.** Reserved for future codification purposes.

26 **"§ 90-113.140. Annual report.**

27 (a) The Department, in consultation with the Commission and the Advisory Board, shall
28 report annually on the effectiveness of the medical cannabis program operated pursuant to this
29 Article and recommendations for any changes to the program. The report shall, without
30 disclosing any identifying information about cardholders, physicians, qualified patients,
31 designated caregivers, or suppliers, contain the following, at a minimum:

- 32 (1) The number of registry identification card applications submitted, approved,
33 and renewed.
- 34 (2) The number of qualifying patients and designated caregivers served by each
35 medical cannabis center during the report year.
- 36 (3) The nature of the debilitating medical conditions of the qualifying patients and
37 a breakdown of qualifying patients by age group.
- 38 (4) The new debilitating medical conditions added by the Advisory Board, if any.
- 39 (5) The efficacy of or satisfaction with cannabis and cannabis-infused products
40 on a yes-no questionnaire as submitted by qualifying patients in a voluntary,
41 anonymous survey, which may be conducted online or through medical
42 cannabis centers.
- 43 (6) The number of registry identification cards denied, suspended, or revoked.
- 44 (7) The number of physicians providing written certifications for qualifying
45 patients.
- 46 (8) The number of suppliers, production facilities, and medical cannabis centers
47 by county.

48 (b) The report shall be submitted to the Joint Legislative Oversight Committee on Health
49 and Human Services and to the Joint Legislative Oversight Committee on Justice and Public
50 Safety by October 1 of each year, beginning in 2022.

51 **"§ 90-113.141. Construction of Article.**

1 This Article shall not be construed to do any of the following:

- 2 (1) Allow for a violation of any law other than for conduct in compliance with the
3 provisions of this Article.
- 4 (2) Affect or repeal laws relating to nonmedical use, possession, production, or
5 sale of cannabis.
- 6 (3) Authorize the use of cannabis by anyone other than a qualified patient.
- 7 (4) Permit the operation of any vehicle, aircraft, train, or boat while under the
8 influence of cannabis.
- 9 (5) Require the violation of federal law or purport to give immunity under federal
10 law.
- 11 (6) Require any accommodation of any on-site medical use of cannabis in any
12 correctional institution or detention facility or place of education or
13 employment, or of smoking or vaping cannabis in any public place.
- 14 (7) Require a health insurance provider, health care plan, property and casualty
15 insurer, or medical assistance program to be liable for or reimburse a claim
16 for the medical use of cannabis. Consultations in which physicians diagnose
17 debilitating medical conditions and complete written certifications shall be
18 reimbursed consistent with any other visit to a health care facility.
- 19 (8) Affect or repeal laws relating to negligence or professional malpractice on the
20 part of a qualified patient, designated caregiver, physician, supplier, or
21 supplier's agents or employees.
- 22 (9) Impair the ability of any party to prohibit or limit smoking or vaping of
23 cannabis on his or her private property.
- 24 (10) Impair the ability of a community association to prohibit or limit smoking or
25 vaping of cannabis in a common area through the community association's
26 declaration or bylaws.

27 **"§ 90-113.142. Severability.**

28 The provisions of this Article are severable. If any provision of this Article is held invalid by
29 a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article
30 which can be given effect without the invalid provision."

31 **SECTION 2.(a)** The initial appointments made to the Compassionate Use Advisory
32 Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this
33 act. In order to provide for the staggering of terms, the initial term for each member appointed
34 under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed
35 pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall
36 represent a potential registry identification cardholder with a debilitating medical condition who
37 intends to use cannabis and a parent of a minor qualified patient with a debilitating medical
38 condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant
39 to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In
40 order to allow for the staggering of terms, the initial term for each member appointed pursuant
41 to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed
42 pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years;
43 and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be
44 one year. Subsequent appointments shall be for the full four-year term in accordance with
45 G.S. 90-113.113(b).

46 **SECTION 2.(b)** The initial appointments made to the Medical Cannabis Production
47 Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date
48 of this act, and the Commission must hold their first meeting not later than 60 days after the
49 effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules,
50 as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required
51 by G.S. 90-113.119. In order to provide for the staggering of terms, the initial term for each

1 member appointed under G.S. 90-113.118(a)(1)a. and (a)(7) shall be one year. The initial term
 2 for members appointed pursuant to G.S. 90-113.118(8) through (9) shall be two years. The initial
 3 term for members appointed pursuant to G.S. 90-113.118(a)(1)b. shall be three years. The initial
 4 term for members appointed pursuant to G.S. 90-113.118(5) through (6) shall be four years.
 5 Subsequent appointments shall be for the full four-year term in accordance with
 6 G.S. 90-113.118(b).

7 **SECTION 2.(c)** Within 270 days of the effective date of this act, the North Carolina
 8 Medical Care Commission must adopt rules as required by G.S. 90-113.115(h).

9 **SECTION 2.(d)** No later than 30 days after the effective date of this act, the North
 10 Carolina Medical Board shall approve a three-hour continuing medical education course and a
 11 one-hour supplemental medical education course on cannabis and cannabis-infused products.

12 **SECTION 3.** G.S. 105-164.13 reads as rewritten:

13 **"§ 105-164.13. Retail sales and use tax.**

14 The sale at retail and the use, storage, or consumption in this State of the following items are
 15 specifically exempted from the tax imposed by this Article:

- 16 ...
- 17 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a
 18 registry identification cardholder. The terms "cannabis," "cannabis-infused
 19 product," "medical cannabis center," and "registry identification cardholder"
 20 have the same meanings as defined in G.S. 90-113.112.

21"

22 **SECTION 4.** G.S. 106-121 reads as rewritten:

23 **"§ 106-121. Definitions and general consideration.**

24 For the purpose of this Article:

25 ...

26 (6) The term "drug" means all of the following:

- 27 a. Articles recognized in the official United States Pharmacopoeia,
 28 official Homeopathic Pharmacopoeia of the United States, or official
 29 National Formulary, or any supplement to any of ~~them;~~ and them.
 30 b. Articles intended for use in the diagnosis, cure, mitigation, treatment
 31 or prevention of disease in man or other ~~animals;~~ and animals, except
 32 for cannabis or cannabis-infused products, as defined in
 33 G.S. 90-113.114, that are manufactured by a production facility or sold
 34 by a medical cannabis center, as defined in G.S. 90-113.112.
 35 c. Articles (other than food) intended to affect the structure or any
 36 function of the body of man or other ~~animals;~~ and animals.
 37 d. Articles intended for use as a component of any article specified in
 38 paragraphs a, b or c; but does not include devices or their components,
 39 parts, or accessories.

40 ...

41 (8) The term "food" means all of the following:

- 42 a. Articles used for food or drink for man or other animals, except for
 43 cannabis or cannabis-infused products, as defined in G.S. 90-113.112,
 44 that are manufactured by a production facility or sold by a medical
 45 cannabis center, as defined in G.S. 90-113.112.
 46 b. Chewing ~~gum;~~ and gum.
 47 c. Articles used for components of any such article.

48"

49 **SECTION 4.5.(a)** G.S. 15A-974 reads as rewritten:

50 **"§ 15A-974. Exclusion or suppression of unlawfully obtained evidence.**

51 (a) Upon timely motion, evidence must be suppressed if:

- 1 (1) Its exclusion is required by the Constitution of the United States or the
2 Constitution of the State of North Carolina; or
3 (2) It is obtained as a result of a substantial violation of the provisions of this
4 Chapter. In determining whether a violation is substantial, the court must
5 consider all the circumstances, including:
6 a. The importance of the particular interest violated;
7 b. The extent of the deviation from lawful conduct;
8 c. The extent to which the violation was willful;
9 d. The extent to which exclusion will tend to deter future violations of
10 this Chapter.

11 Evidence shall not be suppressed under this subdivision if the person
12 committing the violation of the provision or provisions under this Chapter
13 acted under the objectively reasonable, good faith belief that the actions were
14 lawful.

15 (a1) If evidence was obtained as the result of a search that was supported by probable
16 cause at the time of the search, no evidence obtained as a result of that search shall be suppressed
17 solely on the basis of either of the following:

- 18 (1) A subsequent determination that a substance believed to be a controlled
19 substance at the time of the search was not a controlled substance.
20 (2) A subsequent determination that the presence of a controlled substance at the
21 time of the search was not a violation of law.

22 (b) The court, in making a determination whether or not evidence shall be suppressed
23 under this section, shall make findings of fact and conclusions of law which shall be included in
24 the record, pursuant to G.S. 15A-977(f)."

25 **SECTION 4.5.(b)** This section becomes effective December 1, 2021, and applies to
26 motions filed on or after that date.

27 **SECTION 5.** G.S. 90-87(16) reads as rewritten:

28 "(16) "Marijuana" means all parts of the plant of the genus Cannabis, whether
29 growing or not; the seeds thereof; the resin extracted from any part of such
30 plant; and every compound, manufacture, salt, derivative, mixture, or
31 preparation of such plant, its seeds or resin, but shall not include the mature
32 stalks of such plant, fiber produced from such stalks, oil, or cake made from
33 the seeds of such plant, any other compound, manufacture, salt, derivative,
34 mixture, or preparation of such mature stalks (except the resin extracted
35 therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is
36 incapable of germination. The term does not include industrial hemp as
37 defined in G.S. 106-568.51, when the industrial hemp is produced and used in
38 compliance with rules issued by the North Carolina Industrial Hemp
39 Commission. The term does not include an adequate supply as defined in
40 G.S. 90-113.112 of cannabis for medical use in compliance with Article 5H
41 of Chapter 90 of the General Statutes."

42 **SECTION 6.** This act is effective when it becomes law and applies to acts committed
43 on and after that date.